Cytel is one of the leading global providers of clinical trial design SaaS software, biometric services and advanced analytics, focusing on optimising clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data.
Company Background
- Actively support and accelerate its next phase of growth and innovation by investing in Cytel's business and software offering.
- Leverage the company's full potential to increase speed, productivity and efficiency of clinical trials to improve human health by transforming intelligence into confident decisions.
Vision & Outlook
- Actively support and accelerate its next phase of growth and innovation by investing in Cytel's business and software offering.
- Leverage the company's full potential to increase speed, productivity and efficiency of clinical trials to improve human health by transforming intelligence into confident decisions.
Updates & Highlights:
- In 2024, Cytel’s GHG emissions reduction targets were validated by the Science-Based Targets initiative (SBTi).
- In 2024, launch of the East Horizon platform to enhance adaptive clinical trial design by integrating East® software with cloud computing and advanced design capabilities.
- In 2024, announced strategic partnership with OneMedNet to enhance data-driven healthcare solutions.
SECTOR
Technology & Payments
Healthcare
REVENUES 2023
EUR 265 million
EMPLOYEES
1,500
OWNERSHIP
Fund X
INVESTMENT DATE
2021
HEAD OFFICE
Waltham, Massachusetts, USA
